Literature DB >> 19890060

Intranasal immunization promotes th17 immune responses.

Beata M Zygmunt1, Faiza Rharbaoui, Lothar Groebe, Carlos A Guzman.   

Abstract

Th17 cells are a lineage of CD4+ T cells characterized by IL-17 secretion, which plays a crucial role in immune responses against important respiratory pathogens, such as Mycobacterium tuberculosis. In this study, we demonstrated that intranasal (i.n.) immunization leads per se to Th17-biased immune responses, regardless of the adjuvant used. The activated CD4+ T cells also showed an up-regulated expression of the chemokine receptor CCR6, which is a marker for murine Th17 cells. These results have important implications in the context of optimizing rational vaccine design, since i.n. immunization appears to be the strategy of choice for situations where the induction of a Th17 phenotype would be beneficial.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19890060     DOI: 10.4049/jimmunol.0901144

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia.

Authors:  Weihui Wu; Jin Huang; Biyan Duan; David C Traficante; Haeyeon Hong; Martina Risech; Stephen Lory; Gregory P Priebe
Journal:  Am J Respir Crit Care Med       Date:  2012-06-21       Impact factor: 21.405

2.  Immunological considerations in the development of Pseudomonas aeruginosa vaccines.

Authors:  Sarah M Baker; James B McLachlan; Lisa A Morici
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

Review 3.  Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.

Authors:  Mevyn Nizard; Mariana O Diniz; Helene Roussel; Thi Tran; Luis Cs Ferreira; Cecile Badoual; Eric Tartour
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 4.  Current prospects and future challenges for nasal vaccine delivery.

Authors:  Helmy Yusuf; Vicky Kett
Journal:  Hum Vaccin Immunother       Date:  2016-12-09       Impact factor: 3.452

5.  Recognition of conserved antigens by Th17 cells provides broad protection against pulmonary Haemophilus influenzae infection.

Authors:  Wenchao Li; Xinyun Zhang; Ying Yang; Qingqin Yin; Yan Wang; Yong Li; Chuan Wang; Sandy M Wong; Ying Wang; Howard Goldfine; Brian J Akerley; Hao Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-09       Impact factor: 11.205

6.  Specific T cell induction using iron oxide based nanoparticles as subunit vaccine adjuvant.

Authors:  Lázaro Moreira Marques Neto; Nicholas Zufelato; Ailton Antônio de Sousa-Júnior; Monalisa Martins Trentini; Adeliane Castro da Costa; Andris Figueiroa Bakuzis; André Kipnis; Ana Paula Junqueira-Kipnis
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

7.  Location of CD4+ T cell priming regulates the differentiation of Th1 and Th17 cells and their contribution to arthritis.

Authors:  Rachel Rodeghero; Yanxia Cao; Susan A Olalekan; Yoichiro Iwakua; Tibor T Glant; Alison Finnegan
Journal:  J Immunol       Date:  2013-04-29       Impact factor: 5.422

8.  Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production.

Authors:  Afton L Thompson; Brandi T Johnson; Gregory D Sempowski; Michael D Gunn; Baidong Hou; Anthony L DeFranco; Herman F Staats
Journal:  J Immunol       Date:  2012-02-15       Impact factor: 5.422

9.  Airway epithelial NF-κB activation promotes allergic sensitization to an innocuous inhaled antigen.

Authors:  Jennifer L Ather; Samantha R Hodgkins; Yvonne M W Janssen-Heininger; Matthew E Poynter
Journal:  Am J Respir Cell Mol Biol       Date:  2010-06-25       Impact factor: 6.914

Review 10.  Vaccines for Pseudomonas aeruginosa: a long and winding road.

Authors:  Gregory P Priebe; Joanna B Goldberg
Journal:  Expert Rev Vaccines       Date:  2014-02-27       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.